



# Assessing trends in utilization and off-label prescribing for Ozempic, a glucagon-like peptide receptor agonist

Elyse Muñoz, PhD<sup>1</sup>; Kimesha Grant, MPH, RN<sup>1</sup>; Rosenie Thelus, PhD, MPH<sup>1</sup>; Alex Secora, PhD<sup>1</sup>  
<sup>1</sup>IQVIA, Falls Church, US

## Introduction

- There has been tremendous public interest in the use of glucagon-like peptide receptor agonists (GLP-1 RAs) given their efficacy in weight loss.
- Ozempic® (semaglutide), which only has a type 2 diabetes indication, is potentially being used off-label in several disease areas.

## Objective

- Evaluate trends in Ozempic® prescribing practices to understand and inform pharmacovigilance efforts on GLP-1 RAs.

## Methods







### National Prescription Audit (NPA):

- Captures over 94% of all outpatient prescription activity in the U.S. and covers all products, classes, and manufacturers.
- Used to identify national and regional prescriptions dispensed data; NPA – Extended Insights was used for provider specialty data.

### National Medical and Treatment Audit (NMTA):

- Provides unprojected analysis of diagnoses, markets, products, patients, and HCPs over time from 1.5 billion annual professional claims and over 4 billion pharmacy claims.
- Used to identify diagnosis codes and demographics associated with prescriptions written from office-based medical practices.

## Results



## Key Insights

- In 2023 there were 51.9 million prescriptions dispensed for GLP-1 RAs approved for diabetes, with Ozempic® representing ~43% of the prescriptions with 22.1 million.
- From 2018 to 2023, ~68% of Ozempic® prescriptions were dispensed to female patients, with most dispensed to those 40-59 (~50%) and 60+ years old (~33%).
- In 2023, nurse practitioners (NPs) were the second largest prescribers, representing a ~69% increase over 2022.
- Ozempic® was the only GLP-1 RA brand in the class with readily identifiable off-label prescribing, increasing from ~22% in 2018 to ~27% in 2023 primarily for obesity.
- Off label prescribing for Ozempic peaked in 2022 and close to 50% of those prescriptions were prescribed via telehealth.

## Conclusion

- Ozempic® is currently used off-label more than any other GLP-1 RA to treat obesity-related conditions.
- Though off-label uses are emerging, including in alcohol use disorder and women's health, widespread use has not been adopted.

## Slide 1

---

**TR0** Is there a way to put the drug names in lower case? Also, maybe move the title more to middle or put on top?

Thelus, Rosenie, 2024-04-29T17:15:00.038

**TR1** Is the y-axis the number of patients, visits or Rx?

Thelus, Rosenie, 2024-04-29T17:17:41.723

**GK1 0** [@Thelus, Rosenie] visits. Should I also add axis labels?

Grant, Kimesha, 2024-04-29T17:47:57.114

**TR2** Text seems a bit crowded...maybe reduce to 24 or 26?

Thelus, Rosenie, 2024-04-29T17:20:04.368

**TR3** I'm not tracking where this number is coming from? Would be good to have fig # for reference. It looks like 22.1 from the figure.

Thelus, Rosenie, 2024-04-29T17:26:58.792

**GK3 0** [@Thelus, Rosenie] the decimal was in the wrong place. Thank you for catching that! It's fixed now. Is it clear now or should we add figures for each of the results?

Grant, Kimesha, 2024-04-29T17:47:20.571